Shanghai Haohai Biological Technology Co., Ltd. (FRA:5HB)

Market Cap	1.26B
Revenue (ttm)	299.77M
Net Income (ttm)	46.00M
Shares Out	n/a
EPS (ttm)	0.20
PE Ratio	27.40
Forward PE	n/a
Dividend	0.12 (4.01%)
Ex-Dividend Date	Sep 5, 2025

Volume	n/a
Average Volume	0
Open	2.960
Previous Close	3.000
Day's Range	2.960 - 2.980
52-Week Range	2.560 - 3.400
Beta	n/a
RSI	49.66
Earnings Date	Mar 22, 2026

About FRA:5HB

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyaluronate gel, anti-adhesion, and burn wound related products. In addition, it provides injectors, scalpels, suture needles and other products. Further, ...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 2,156
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5HB

Financial Performance

In 2024, FRA:5HB's revenue was 2.68 billion, an increase of 1.70% compared to the previous year's 2.63 billion. Earnings were 420.45 million, an increase of 1.04%.

Financial numbers in CNY